Seven Korean medical centers to collaborate on studies of immunosuppression
in kidney transplant patients and role of cell-mediated immunity
COLUMBIA, Md., Aug. 28 /PRNewswire/ -- "Cylex, Inc., in association with our Korean distributor, Sun Woo Biotech, is delighted to be able to announce our support for a major, multi-center trial of the ImmuKnow assay for cell-mediated immunity at seven highly respected medical institutions in the Republic of Korea," stated Brad Stewart, president of Cylex. "It is a critical goal for the Company to be able to demonstrate the effectiveness of the ImmuKnow assay in transplant populations of different ethnicities by working with specialized institutions around the world."
In the Republic of Korea, a multi-center consortium of kidney transplant centers will use the ImmuKnow assay to assess cell-mediated immunity of 238 patients between the ages of 15 and 60 who undergo an initial kidney transplant and who are randomly assigned to receive either triple immunosuppressive therapy (tacrolimus + mycophenolate mofetil + prednisone) or steroid-free immunosuppression (tacrolimus + mycophenolate mofetil only).
The seven institutions that will participate in this clinical trial
-- Samsung Medical Center (in Seoul)
-- KangNam St. Mary's Hospital (in Seoul)
-- Kyungpook National University Hospital (in Daegu)
-- Ajou University Hospital (in Suwon)
-- Daejeon St. Mary's Hospital (in Daegeon)
-- Soon Chun Hyang University Hospital (in Seoul)
-- Bong Seng Memorial Hospital (in Busan)
The ImmuKnow assay will be used to monitor all patients over a period
of 36 months from initiation of treatment to assess the value of the assay
predicting risk for organ rejection, in predicting risk for infection, and
managing patients' immunosuppressed status with a goal of optimizing
survival and minimizing organ rejection. Patients will have blood drawn and
|SOURCE Cylex, Inc.|
Copyright©2008 PR Newswire.
All rights reserved